Articles
Volume 4 Supplement 2
Current perspectives on the treatment of rheumatic diseases with infliximab
Reviews
Edited by Peter E Lipsky and Ravinder N Maini
Supported by an educational grant from Centocor, Inc.
|
Supplement
The determination and measurement of functional disability in rheumatoid arthritis Frederick Wolfe Arthritis Res 2002, 4(Suppl 2):S11-S15 (8 April 2002) |
|
Supplement
Current and future management approaches for rheumatoid arthritis Ferdinand C Breedveld Arthritis Res 2002, 4(Suppl 2):S16-S21 (27 March 2002) |
|
Supplement
How does infliximab work in rheumatoid arthritis? Ravinder N Maini, Marc Feldmann Arthritis Res 2002, 4(Suppl 2):S22-S28 (27 March 2002) |
|
Supplement
Structural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde Arthritis Res 2002, 4(Suppl 2):S29-S33 (27 March 2002) |
|
Supplement
Autoantibodies in rheumatoid arthritis and their clinical significance Günter Steiner, Josef Smolen Arthritis Res 2002, 4(Suppl 2):S1-S5 (26 April 2002) |
|
Supplement
Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases Joachim R Kalden Arthritis Res 2002, 4(Suppl 2):S34-S40 (24 May 2002) |
|
Supplement
Paul Emery Arthritis Res 2002, 4(Suppl 2):S6-S10 (18 April 2002) |
